Shanthi Ganesh

Novo Nordisk (Denmark) — Denmark

Biochemistry, Genetics and Molecular Biology · Life Sciences

25h-index3.2kcitations89works7.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

RNA Interference and Gene Delivery(21), Virus-based gene therapy research(18), RNA modifications and cancer(12), Cancer Research and Treatments(11), RNA Research and Splicing(10)

Publications89 total

Abstract 3283: RNAi mediated silencing of <i>STAT3 or PD-L1</i> in tumor-associated immune cells induces robust anti-tumor effects in immunotherapy resistant tumors
Cancer Research·2025
RNAi mediated silencing of STAT3/PD-L1 in tumor-associated immune cells induces robust anti-tumor effects in immunotherapy resistant tumors
Molecular Therapy·2024· 21 citedOpen Access
Abstract 6539: RNAi mediated silencing of <i>STAT3</i> in tumor-associated immune cells induces robust anti-tumor effects in immunotherapy resistant tumors
Cancer Research·2024
Supplemental figures S1-9 from Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin
2023Open Access
Data from β-Catenin mRNA Silencing and MEK Inhibition Display Synergistic Efficacy in Preclinical Tumor Models
2023Open Access
Supplementary legends from β-Catenin mRNA Silencing and MEK Inhibition Display Synergistic Efficacy in Preclinical Tumor Models
2023Open Access
supplemental figure legends from Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin
2023Open Access
supplemental figure legends from Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin
2023Open Access
Data from Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin
2023Open Access
Data from β-Catenin mRNA Silencing and MEK Inhibition Display Synergistic Efficacy in Preclinical Tumor Models
2023Open Access
Data from Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin
2023Open Access
Figure S1, Figure S2, Figure S3 from β-Catenin mRNA Silencing and MEK Inhibition Display Synergistic Efficacy in Preclinical Tumor Models
2023Open Access
Figure S1, Figure S2, Figure S3 from β-Catenin mRNA Silencing and MEK Inhibition Display Synergistic Efficacy in Preclinical Tumor Models
2023Open Access
Supplemental figures S1-9 from Direct Pharmacological Inhibition of β-Catenin by RNA Interference in Tumors of Diverse Origin
2023Open Access
Supplementary legends from β-Catenin mRNA Silencing and MEK Inhibition Display Synergistic Efficacy in Preclinical Tumor Models
2023Open Access
Supplementary Figure Legend from Relaxin-Expressing, Fiber Chimeric Oncolytic Adenovirus Prolongs Survival of Tumor-Bearing Mice
2023Open Access
Data from Relaxin-Expressing, Fiber Chimeric Oncolytic Adenovirus Prolongs Survival of Tumor-Bearing Mice
2023Open Access
Data from Relaxin-Expressing, Fiber Chimeric Oncolytic Adenovirus Prolongs Survival of Tumor-Bearing Mice
2023Open Access
Supplementary Figure Legend from Relaxin-Expressing, Fiber Chimeric Oncolytic Adenovirus Prolongs Survival of Tumor-Bearing Mice
2023Open Access
Supplementary Figure 1 from Relaxin-Expressing, Fiber Chimeric Oncolytic Adenovirus Prolongs Survival of Tumor-Bearing Mice
2023Open Access
page 1 of 5Next →

Frequent Co-authors

Weimin Wang(15), Marc Abrams(12), P. Seshidhar Reddy(11), Mansoor M. Amiji(10), Bob D. Brown(9), Serena Shui(7), Michael Kaleko(6), Sheila Connelly(6), Dongyu Chen(6), Wendy A. Cyr(6), Neeraja Idamakanti(5), Kevin P. Craig(5), Karin Jooss(5), Martin L. Koser(5), Girish R. Chopda(5), Hank Dudek(5), Cheng Lai(5), Terrence W. Brann(4), Arun K. Iyer(3), Dylan Morrissey(3)